• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Argan (AGX) Backlog Debate Meets Strong Growth Forecasts As Fair Value Stays In View

    Simply Wall St·11/14/2026 00:45:39
    Listen to the news

    Argan (AGX) is back in focus after fresh projections flagged sharp year-over-year gains in earnings and revenue, even as the share price recently pulled back and debate around project backlog has intensified.

    Recent trading shows how divided the market is on Argan. The share price is down about 47% over the past 90 days and roughly 16% over 30 days, even after a strong 7 day share price gain of about 10% and a very large 5 year total shareholder return of roughly 7x. This signals that momentum has faded in the short term while debate over backlog strength and cash deployment reshapes how investors weigh that longer track record.

    Scan other construction and infrastructure plays that are showing strong earnings trends and solid balance sheets through our hand-picked list of solid balance sheet and fundamentals (24 results), which share some of Argan’s key qualities.

    Bulls see Argan’s pullback as a mispricing of cash, growth and backlog, while bears point to timing and replenishment risks. Which case does the current valuation actually lean toward?

    Most Popular Narrative: 15% Overvalued

    The narrative fair value for Argan of about $266.82 to $328.44 brackets the last close of $306.48, which keeps the focus squarely on whether recent weakness already reflects the key risks. According to MarkoVT, an investor in the Simply Wall St Community, the discussion turns on how backlog, cash and contract timing interact with that range.

    Key Concerns
    AGX''s power segment remains dominate in revenue generation. Per Zacks article from Nov. 5, 2026: "The key concern is backlog replenishment. Argan''s backlog was $2.52 billion at July-end, down from $2.93 billion at January-end, as project completions outpaced additions. Management includes projects only after receiving a notice to proceed and cited more than $260 million of additions from scope increases and smaller projects. It expects several new projects over the next seven to 15 months, although timing remains uncertain. New awards and project mobilization will therefore be critical to maintaining revenue visibility."

    See why 1 investors see Argan as 15% overvalued.

    Result: Fair Value of $266.82 (OVERVALUED)

    Still, Argan’s concentration in the Power segment, along with the backlog replenishment uncertainty flagged in the July figures, could quickly challenge that fair value story.

    Find out about the key risks to this Argan narrative.

    Next Steps

    If the latest sentiment around Argan feels mixed, that is the point. Use the data yourself and pressure test the optimism baked into those rewards by reviewing the 3 key rewards.

    Looking for more investment ideas beyond Argan?

    Do not stop with Argan. Fresh ideas often come from scanning wider, and a few focused stock groups can quickly sharpen where you put new capital to work.